 | Up a level |
Journal Article
Chen, Robert, Gopal, Ajay K., Smith, Scott E., Ansell, Stephen, Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Huebner, Dirk, Fong, Abraham and Younes, Anas (2015). Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Chen, Robert, Gopal, Ajay K., Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Huebner, Dirk, Fong, Abraham and Younes, Anas (2016). Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood, 128 (12). S. 1562 - 1567. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Chen, Robert W., Gopal, Ajay K., Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Sievers, Eric L. and Younes, Anas (2012). Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 120 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971
Gopal, Ajay K., Chen, Robert, Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Chi, Xuedong, Sievers, Eric L. and Younes, Anas (2015). Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood, 125 (8). S. 1236 - 1244. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Gopal, Ajay K., Chen, Robert, Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Chi, Xuedong, Sievers, Eric L. and Younes, Anas (2015). Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood, 125 (8). S. 1236 - 1244. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Gopal, Ajay K., Pro, Barbara, Connors, Joseph M., Younes, Anas, Engert, Andreas, Shustov, Andrei R., Chi, Xuedong, Larsen, Emily K., Kennedy, Dana A. and Sievers, Eric L. (2016). Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting. Clin. Trials, 13 (5). S. 545 - 555. LONDON: SAGE PUBLICATIONS LTD. ISSN 1740-7753
Huebel, Kai, Ghielmini, Michele, Ladetto, Marco and Gopal, Ajay K. (2020). Controversies in the Treatment of Follicular Lymphoma. Hemasphere, 4 (1). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241
Karuturi, Meghan S., Arai, Sally, Chen, Robert W., Gopal, Ajay K., Feng, Lei, Yuan, Ying, Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Ramchandren, Radhakrishnan, Bartlet, Nancy L., Cheson, Bruce D., Forero-Torres, Andres, Moskowitz, Craig H., Connors, Joseph M., Fanale, Michelle A., de Vos, Sven, Engert, Andreas, Illidge, Tim, Borchmann, Peter, Morschhauser, Franck, Horning, Sandra J. and Younes, Anas (2012). Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. Blood, 120 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971
Sehn, Laurie Helen, Scholz, Christian W., Luminari, Stefano 
ORCID: 0000-0001-8446-2285, Salar, Antonio, Wahlin, Bjorn E., Gopal, Ajay K., Bonnet, Christophe Marc, Paneesha, Shankara, Manzke, Oliver, Seguy, Francis, Li, Di and Huebel, Kai
(2021).
A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
J. Clin. Oncol., 39 (15).
PHILADELPHIA:
LIPPINCOTT WILLIAMS & WILKINS.
ISSN 1527-7755